ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / QTI / news
POCI (31) ITOC (33) ECOR (29) OM (34) ⌘ Pro Terminal →

Why QTI Stock advanced +0.47% Today — RQD Quant Desk Flash

$2.15 +0.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.15

QT Imaging Holdings Inc. (QTI) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $31.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QTI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, QT Imaging Holdings Inc. (NASDAQ: QTI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $2.15 (+0.47% 1D, market cap $31.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, QTI ranks #843 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QTI compare to POCI and ITOC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), QTI carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 45.4%, and ROIC of -35.0%. By comparison, POCI (Precision Optics Corporation Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $51.1M) and ITOC (iTonic Holdings Ltd (Class A)) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $19.0M). Among the 5-stock peer group, QTI leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QTI?
▼

Per QTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001844505), QT Imaging Holdings Inc. generated $18.9M in revenue (+287.9% YoY), -$21.1M in net income, and -$9.1M in free cash flow against $23.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.15 (-0.11%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (5)Whales (3)SEC (8)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
$8 Bull$2 Base$1 Bear
📬 FREE QTI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QTI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY QTI SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (28% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$2.45-4.9% Next Q
Q2 (-2Q)
34
Grade E$2.33-2.1% Next Q
Q3 (-1Q)
32
Grade E$2.28-5.7% Next Q
Current
29
Grade E$2.15-9.8% Hist 90D α
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QTI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QTI currently carries a cautious 29/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.56) and Max Pain ($2.26) forces dealer call-delta covering toward $7.98.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QTI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QTI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why QTI Stock advanced +0.47% Today — RQD Quant Desk Flash

QT Imaging Holdings Inc. (QTI) advanced +0.47% to $2.15, trading at 2% of its 52-week range ($2.14 – $7.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($2.14 – $7.6) with RSI-14 at 33.6 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.15 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 45.4% gross margin and $0 annual free cash flow.
Live QTI Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QTI)

  • ✓Walkthrough of QTI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
QTI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.08%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.21H $2.21L $2.14C $2.15VOL 22.7K
RES: $2.83SUP: $2.12SMA50: $2.56SMA200: $4.44
$16.61$12.69$8.76$4.84$0.92RES $2.83SUP $2.12$2.152026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QTI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QTI Butterfly Map → + Track QTI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +287.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on QTI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QTI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QTI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QTI)

Health Care Rank #843 of 1015 ⚔️ POCI vs QTI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QTI vs. POCI, ITOC, ECOR, OM)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, QT Imaging Holdings Inc. (QTI) ranks #843 by composite RQD confidence (29/100, grade E) and #791 by equity capitalization ($31.3M). Within this direct 5-issuer industry benchmark cohort, QTI leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. OM currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with QTI at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QTI ACTIVE
QT Imaging Holdings Inc.
E 29/100 — 45.4% -35.0% +0.47% $31.3M Benchmark Subject
POCI
Precision Optics Corporation Inc.
E 31/100 — 17.8% -35.0% +3.23% $51.1M /poci-vs-qti →
ITOC
iTonic Holdings Ltd (Class A)
E 33/100 — 62.6% -35.0% -9.61% $19.0M /itoc-vs-qti →
ECOR
electroCore Inc.
E 29/100 — 86.8% -35.0% -4.79% $67.8M /ecor-vs-qti →
OM
Outset Medical Inc.
E 34/100 — 39.1% -28.0% -0.25% $75.8M /om-vs-qti →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001844505 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), QT Imaging Holdings Inc. (QTI) reported GAAP revenue of $18.9M (+287.9% vs. FY2024 revenue of $4.9M , and +46796.3% cumulative change since FY2023) , GAAP net income of -$21.1M, operating cash flow of -$9.0M, and free cash flow of -$9.1M (+10.3% YoY). On the balance sheet, QTI closed FY2025 with $23.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $18.9M -$21.1M -$9.0M -$9.1M $23.0M —
FY2024 (FY) 2024-12-31 $4.9M -$9.0M -$10.0M -$10.1M $6.1M —
FY2023 (FY) 2023-12-31 $40.4K -$6.1M -$2.7M -$2.7M — —

3. QTI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, QT Imaging Holdings Inc. (NASDAQ: QTI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $2.15 (+0.47% 1D, market cap $31.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, QTI ranks #843 in composite RQD confidence.

How does QTI compare to POCI and ITOC in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), QTI carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 45.4%, and ROIC of -35.0%. By comparison, POCI (Precision Optics Corporation Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $51.1M) and ITOC (iTonic Holdings Ltd (Class A)) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $19.0M). Among the 5-stock peer group, QTI leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QTI?

Per QTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001844505), QT Imaging Holdings Inc. generated $18.9M in revenue (+287.9% YoY), -$21.1M in net income, and -$9.1M in free cash flow against $23.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QTI trading relative to its 50-day, 200-day, and 52-week technical levels?

QTI last traded at $2.15 (+0.47% on volume of 15,384 shares), positioning the stock -16.02% below its 50-day simple moving average ($2.56) and -51.58% below its 200-day simple moving average ($4.44). Across its 52-week range of $2.14 to $7.60, QTI sits at the 0.2% percentile with a 14-day RSI of 33.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.88 to $2.42).

Direct Sub-Reports: QTI RQD Cockpit QTI 12M Forecast QTI Earnings & Move QTI Dividends & DRIP QTI Insiders & 13F QTI Whale Options QTI Profit Sankey QTI News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

QTI — QT Imaging Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

QT Imaging Holdings Inc. (QTI) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.15 (+0.47% 1D, market capitalization $31.3M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 45.4%, operating margin of -23.4%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Per the recent news, the company's Breast Acoustic CT™ Scanner is available through a national group purchasing agreement with Premier.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), QT Imaging Holdings Inc. (QTI) reported $18.9M in annual revenue (up from $4.9M in FY2024, +287.9% YoY) and -$21.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($40.4K revenue, -$6.1M net income) through FY2025, QTI scaled operating cash flow to -$9.0M and free cash flow to -$9.1M, backed by $23.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.14 – $7.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -23.4% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The prospective investor should monitor the upcoming Q3 results and any commercial-channel developments, such as adoption through the Premier group purchasing arrangement, as the source-supported ripple points.

  • Key Question #1: Can QTI sustain or expand its -23.4% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $18.9M and free cash flow of -$9.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is QTI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

QTI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for QT Imaging Holdings Inc. (QTI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to QTI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QTI Bull vs. Bear Conversation Board — What's Your Call at $2.15?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QTI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on QTI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $2.61 (+22.0%)
📌 Pinned Debate

Revenue rose from $4.9M in FY 2024 to $18.9M in FY 2025 and an analyst initiated coverage with a Buy rating and $9 target.

Picked up a starter position in QTI in my $100K Virtual Cash book at $2.14. Revenue rose from $4.9M in FY 2024 to $18.9M in FY 2025 and an analyst initiated coverage with a Buy rating and $9 target.. Trading inside a $2.14–$7.60 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Electromedical & Electrotherapeutic Apparatus multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Electromedical & Electrotherapeutic Apparatus. If gross margin (45.4%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $1.82 (-15.0%)
Spot @ $2.14

Negative ROIC of -35%, a 0% FCF yield, and an Altman Z-Score of 0.2 signal weak cash generation and elevated financial-distress risk.

Negative ROIC of -35%, a 0% FCF yield, and an Altman Z-Score of 0.2 signal weak cash generation and elevated financial-distress risk.. Look at the math on QTI: paying current EV/EBITDA multiples for -35.0% ROIC and -23.4% operating margins leaves zero margin of safety if Biotechnology: Electromedical & Electrotherapeutic Apparatus demand softens. I'd wait for a retest of $1.88 before getting long.

LIVE TAPE